Volta Medical SAS

Volta Medical présente les résultats du premier essai transatlantique contrôlé et randomisé comparant l’ablation assistée par l’IA au traitement conventionnel pour la fibrillation atriale persistante

Volta Medical presents results from first transatlantic randomized controlled trial comparing AI-assisted ablation procedure with conventional treatment for persistent atrial fibrillation patients

Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation

Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA

Volta Medical annoncera les résultats de l’essai clinique randomisé TAILORED-AF lors des sessions Late-Breaking du congrès Heart Rhythm 2024 à Boston, MA, États-Unis

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication

Volta Medical führt neuartige, auf Künstlicher Intelligenz basierende Technologie VX1 zur Behandlung von persistierenden Herzrhythmusstörungen an ausgewählten klinischen Zentren in Deutschland ein